Lymphoepithelial carcinoma is a rare salivary gland cancer, most often in the parotid, that is common in Inuit and southern Chinese people and often linked to Epstein-Barr virus. Surgery and radiotherapy give a fairly good outlook.
What is lymphoepithelial carcinoma of the salivary gland?
Lymphoepithelial carcinoma (LEC) of the salivary gland is a rare cancer that most often starts in the parotid gland, the large salivary gland in front of the ear. Under the microscope it is made of sheets of poorly formed cancer cells mixed with large numbers of lymphocytes, a type of white blood cell. The name reflects these two parts: “lympho” for the immune cells and “epithelial” for the cancer cells.
The tumour is much more common in some populations. It is seen most often in Inuit people of the Arctic and in people from southern China and South-East Asia. In these groups it is closely linked to the Epstein-Barr virus (EBV), the virus that causes glandular fever. In other parts of the world it is very uncommon and less often linked to EBV.
Older names for this tumour include “malignant lymphoepithelial lesion” and “undifferentiated carcinoma with lymphoid stroma”. It accounts for well under 1% of all salivary gland cancers (Zhan et al., 2016).
How it differs from nasopharyngeal carcinoma
Salivary LEC looks almost identical under the microscope to the most common form of nasopharyngeal carcinoma, the cancer at the back of the nose described on our page on nasopharyngeal carcinoma. Both are often EBV-related, and both are common in the same populations.
The key difference is where the cancer starts. Nasopharyngeal carcinoma often spreads early to the lymph nodes of the neck and around the parotid. For this reason, doctors must examine the nasopharynx carefully before they can say that a parotid tumour is a true salivary LEC rather than a spread from the nose area. The treatment plans for the two cancers are different.
1. Key facts at a glance
2. Types
By EBV status and region
A systematic review of 295 cases found EBV in about half of tumours tested. Most EBV-positive cases came from endemic populations, but survival did not differ clearly by EBV status (Gibbs et al., 2026).
By gland
3. Causes and risk factors
What does EBV have to do with it?
EBV infects most adults worldwide and usually causes no harm. In a small number of people, the virus takes part in turning normal cells into cancer cells. Genetic background and environment probably explain why this happens far more in certain populations. In a series of 16 patients from an ethnically mixed population, all Asian patients had EBV-positive tumours, but so did a third of non-Asian patients (Whaley et al., 2020).
4. How does it look
In the head and neck
On scans
Under the microscope
5. Symptoms
Common symptoms
- A painless lump in front of the ear or under the jaw
- A lump that slowly grows over weeks or months
- Swollen lymph nodes in the neck
Less common symptoms
Symptoms that suggest a nasopharyngeal origin
How long do symptoms last before diagnosis?
In the series of 16 patients, people had noticed their swelling for close to a year on average before they were diagnosed (Whaley et al., 2020). A slow, painless lump is easy to ignore, so it is worth getting any persistent swelling checked.
When to seek medical advice
Any lump in the salivary gland or neck that lasts more than three weeks should be checked. Seek advice sooner if the face becomes weak or the lump grows quickly.
6. Diagnosis
A Taiwanese series found EBV in most tumours, yet only a few patients had measurable EBV DNA in their blood. The authors concluded that blood EBV DNA cannot yet be relied on to guide treatment in this cancer (Chou et al., 2022).
Staging
Salivary LEC is staged with the TNM system for major salivary gland cancers.
7. Treatment
Treatment is planned by a head and neck multidisciplinary team.
Surgery
Radiotherapy
Radiotherapy after surgery is widely used. In a US National Cancer Database study of 238 people, those who had surgery plus radiotherapy survived longer than those who had surgery alone (Zhan et al., 2016).
Chemotherapy
Side effects
8. Outlook (prognosis)
The outlook is usually better than for many other high-grade salivary gland cancers.
Factors that affect the outlook
Why survival is fairly good
Although the cancer cells look very primitive, salivary LEC often responds well to radiotherapy. The dense lymphocytes around the tumour may also reflect an active immune response against it. Distant spread was rare in the US database, at about 2% of patients, which helps explain why many people are cured with local treatment (Zhan et al., 2016).
9. Follow-up
Visits include examination of the neck and mouth, nasal endoscopy when needed, and scans if symptoms appear. Thyroid blood tests are checked if the neck received radiotherapy, and dental reviews continue for life.
10. Living with lymphoepithelial carcinoma
- Keep your mouth healthy: brush with high-fluoride toothpaste and see your dentist regularly
- Sip water and use saliva substitutes for a dry mouth
- Do jaw and neck exercises to prevent stiffness
- Protect your face from cold if the facial nerve is weak, and use eye drops if the eye does not close fully
- Stop smoking and limit alcohol
- Report new lumps or nasal symptoms without delay
- Seek support from head and neck cancer charities
11. Frequently asked questions
12. Questions to ask your care team
- Has my nasopharynx been examined to rule out spread from there?
- Is my tumour EBV-positive, and does it matter for me?
- What stage is the cancer?
- Will I need a neck dissection?
- Do you recommend radiotherapy or chemotherapy?
- How will treatment affect my face, mouth and swallowing?
- How often will I be checked, and for how long?
Resources
- Chou, C.T., Ou, C.Y., Lee, W.T. and Hsu, H.J. (2022) ‘Clinical features in salivary gland lymphoepithelial carcinoma in 10 patients: case series and literature review’, Laryngoscope Investigative Otolaryngology, 7(3), pp. 779-784.
- Gibbs, H.M. et al. (2026) ‘Lymphoepithelial carcinoma of the salivary gland: a systematic review and single institution experience’, Otolaryngology-Head and Neck Surgery, 174(2), pp. 297-304.
- Whaley, R.D. et al. (2020) ‘Lymphoepithelial carcinoma of salivary gland EBV-association in endemic versus non-endemic patients: a report of 16 cases’, Head and Neck Pathology, 14(4), pp. 1001-1012.
- Zhan, K.Y. et al. (2016) ‘Lymphoepithelial carcinoma of the major salivary glands: predictors of survival in a non-endemic region’, Oral Oncology, 52, pp. 24-29.
- National Cancer Institute (2026) Salivary Gland Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/head-and-neck/hp/adult/salivary-gland-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.